Who We Are
About Us
Our Heritage
Management Team
Responsibility
Environment, Quality and Safety
Ethics and Compliance
Where We Are
Science
Nerve Growth Factor
NETosis
Reparixin
Ladarixin
Pipeline
Publications
Exscalate
Therapeutics
Ophthalmics
Neurotrophic Keratitis
Primary & Speciality Care
Pain and Anti-inflammatory
Prevention
Cough and Cold
Eye, Skin & Oral Care
Cardiovascular
Gastro
Managed Access Programs
Manufacturing
Production Plant
Biotech
Pharma
People & Culture
Media
Press Releases
Dompé in the News
Stories
Media Library

Paolo Pozzilli, MD: Ladarixin, a CXCR1/2 inhibitor, in Type 1 Diabetes

15/06/2020
Published in:
HCP Live
Find out more
Who We Are
About Us
Responsibility
Where We Are
Science
Nerve Growth Factor
NETosis
Pipeline
Publications
Exscalate
Therapeutics
Primary & Speciality Care
Managed Access Programmes
Manufacturing
Production Plant
People & Culture
People & Culture
Media
Press Releases
Dompé in the News
Stories
Media Library
Contact
Contact Form
Linkedin
Twitter

PHARMACOVIGILANCE and VIGILANCE

TO REPORT AN ADVERSE EVENT OF A DOMPÉ PRODUCT CLICK HERE

WHISTLEBLOWING

_

Dompé farmaceutici S.p.A. Single shareholder company / Share capital € 50.000.000,00

REA MI 289519 - A registered company in Milan, Italy / Tax code and VAT number IT00791570153

This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. 

Privacy Policy / Terms of Service / Cookie Policy / Sitemap
© 2024 Dompé. All rights reserved.
GlobalITUS